Literature DB >> 29456084

Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.

X Shawn Liu1, Hao Wu2, Marine Krzisch1, Xuebing Wu1, John Graef3, Julien Muffat1, Denes Hnisz1, Charles H Li4, Bingbing Yuan1, Chuanyun Xu1, Yun Li1, Dan Vershkov5, Angela Cacace3, Richard A Young4, Rudolf Jaenisch6.   

Abstract

Fragile X syndrome (FXS), the most common genetic form of intellectual disability in males, is caused by silencing of the FMR1 gene associated with hypermethylation of the CGG expansion mutation in the 5' UTR of FMR1 in FXS patients. Here, we applied recently developed DNA methylation editing tools to reverse this hypermethylation event. Targeted demethylation of the CGG expansion by dCas9-Tet1/single guide RNA (sgRNA) switched the heterochromatin status of the upstream FMR1 promoter to an active chromatin state, restoring a persistent expression of FMR1 in FXS iPSCs. Neurons derived from methylation-edited FXS iPSCs rescued the electrophysiological abnormalities and restored a wild-type phenotype upon the mutant neurons. FMR1 expression in edited neurons was maintained in vivo after engrafting into the mouse brain. Finally, demethylation of the CGG repeats in post-mitotic FXS neurons also reactivated FMR1. Our data establish that demethylation of the CGG expansion is sufficient for FMR1 reactivation, suggesting potential therapeutic strategies for FXS.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CGG repeats; CRISPR/Cas9; DNA methylation editing; FMR1 reactivation; fragile X syndrome

Mesh:

Substances:

Year:  2018        PMID: 29456084      PMCID: PMC6375087          DOI: 10.1016/j.cell.2018.01.012

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  71 in total

1.  CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.

Authors:  Cong Huai; Chenqiang Jia; Ruilin Sun; Peipei Xu; Taishan Min; Qihan Wang; Chengde Zheng; Hongyan Chen; Daru Lu
Journal:  Hum Genet       Date:  2017-05-15       Impact factor: 4.132

2.  The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery.

Authors:  David J Brick; Hubert E Nethercott; Samantha Montesano; Maria G Banuelos; Alexander E Stover; Soleil Sun Schutte; Diane K O'Dowd; Randi J Hagerman; Michele Ono; David R Hessl; Flora Tassone; Philip H Schwartz
Journal:  Stem Cells Transl Med       Date:  2014-10-01       Impact factor: 6.940

3.  Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium.

Authors: 
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

4.  Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.

Authors:  Shervin Gholizadeh; Jason Arsenault; Ingrid Cong Yang Xuan; Laura K Pacey; David R Hampson
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

5.  RNA-guided human genome engineering via Cas9.

Authors:  Prashant Mali; Luhan Yang; Kevin M Esvelt; John Aach; Marc Guell; James E DiCarlo; Julie E Norville; George M Church
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

6.  Human DNA methylomes at base resolution show widespread epigenomic differences.

Authors:  Ryan Lister; Mattia Pelizzola; Robert H Dowen; R David Hawkins; Gary Hon; Julian Tonti-Filippini; Joseph R Nery; Leonard Lee; Zhen Ye; Que-Minh Ngo; Lee Edsall; Jessica Antosiewicz-Bourget; Ron Stewart; Victor Ruotti; A Harvey Millar; James A Thomson; Bing Ren; Joseph R Ecker
Journal:  Nature       Date:  2009-10-14       Impact factor: 49.962

7.  One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.

Authors:  Haoyi Wang; Hui Yang; Chikdu S Shivalila; Meelad M Dawlaty; Albert W Cheng; Feng Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2013-05-02       Impact factor: 41.582

8.  Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome.

Authors:  Nina Xie; He Gong; Joshua A Suhl; Pankaj Chopra; Tao Wang; Stephen T Warren
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

9.  CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.

Authors:  Samrat Roy Choudhury; Yi Cui; Katarzyna Lubecka; Barbara Stefanska; Joseph Irudayaraj
Journal:  Oncotarget       Date:  2016-07-19

Review 10.  Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome.

Authors:  Elisabetta Tabolacci; Federica Palumbo; Veronica Nobile; Giovanni Neri
Journal:  Genes (Basel)       Date:  2016-08-17       Impact factor: 4.096

View more
  121 in total

1.  Genome, Epigenome, and Transcriptome Editing via Chemical Modification of Nucleobases in Living Cells.

Authors:  Brodie L Ranzau; Alexis C Komor
Journal:  Biochemistry       Date:  2018-12-12       Impact factor: 3.162

Review 2.  CRISPR technologies for precise epigenome editing.

Authors:  Muneaki Nakamura; Yuchen Gao; Antonia A Dominguez; Lei S Qi
Journal:  Nat Cell Biol       Date:  2021-01-08       Impact factor: 28.824

Review 3.  Understanding 3D genome organization by multidisciplinary methods.

Authors:  Ivana Jerkovic; Giacomo Cavalli
Journal:  Nat Rev Mol Cell Biol       Date:  2021-05-05       Impact factor: 94.444

Review 4.  Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins.

Authors:  Ning Jia; Dinshaw J Patel
Journal:  Nat Rev Mol Cell Biol       Date:  2021-06-04       Impact factor: 94.444

5.  When maternal periconceptional diet affects neurological development, it's time to think.

Authors:  Kevin D Sinclair
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-05       Impact factor: 11.205

Review 6.  The Molecular Basis of Drug Addiction: Linking Epigenetic to Synaptic and Circuit Mechanisms.

Authors:  Eric J Nestler; Christian Lüscher
Journal:  Neuron       Date:  2019-04-03       Impact factor: 17.173

7.  Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.

Authors:  Boris Kantor; Lidia Tagliafierro; Jeffrey Gu; Madison E Zamora; Ekaterina Ilich; Carole Grenier; Zhiqing Y Huang; Susan Murphy; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2018-08-29       Impact factor: 11.454

Review 8.  CRISPR System: A High-throughput Toolbox for Research and Treatment of Parkinson's Disease.

Authors:  Fatemeh Safari; Gholamreza Hatam; Abbas Behzad Behbahani; Vahid Rezaei; Mazyar Barekati-Mowahed; Peyman Petramfar; Farzaneh Khademi
Journal:  Cell Mol Neurobiol       Date:  2019-11-26       Impact factor: 5.046

Review 9.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Authors:  Dan Wang; Feng Zhang; Guangping Gao
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

Review 10.  In vivo epigenome editing and transcriptional modulation using CRISPR technology.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  Transgenic Res       Date:  2018-10-04       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.